Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022
Elicera Therapeutics AB (publ) Year-end Report 1 January – 31 December 2022 Fourth quarter (October-December 2022) · Operating profit/loss totaled SEK -3,951,799 (-2,142,267). · Loss for the period totaled SEK -3,898,340 (-2,142,267). · Cash flow from operating activities totaled SEK 5,516,307 (-879,846). · Earnings per share before dilution totaled SEK -0.20 (-0,11). Earnings per share after dilution amounted to SEK -0.20 (-0,11). · Proposed dividend of SEK 0.00 per share (0.00 for the preceding year) Period (January-December 2022) · Operating